FDA ap­proves Lil­ly’s BTK in­hibitor Jaypir­ca for two more blood can­cers

The FDA grant­ed ac­cel­er­at­ed ap­proval to Eli Lil­ly’s Jaypir­ca for cer­tain pa­tients with chron­ic lym­pho­cyt­ic leukemia or small lym­pho­cyt­ic lym­phoma, the In­di­anapo­lis-based phar­ma com­pa­ny an­nounced Fri­day evening.

Adult pa­tients who have re­ceived a pre­vi­ous BTK in­hibitor and a BCL-2 in­hibitor are el­i­gi­ble to re­ceive Jaypir­ca. While Lil­ly’s dai­ly pill is al­so a BTK in­hibitor, it binds re­versibly, un­like oth­er BTK in­hibitors, in­clud­ing Ab­b­Vie and John­son & John­son’s Im­bru­vi­ca, As­traZeneca’s Calquence and BeiGene’s Brukin­sa.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.